A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

Alison T. Stopeck; Joseph M. Unger; Lisa M. Rimsza; William T. Bellamy; Maria Iannone; Daniel Persky; Michael Leblanc; Richard Fisher; Thomas Miller

doi:10.1080/10428190902856808

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

Alison T. Stopeck, Joseph M. Unger, Lisa M. Rimsza, William T. Bellamy, Maria Iannone, Daniel Persky, Michael Leblanc, Richard Fisher, Thomas Miller

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

86 Scopus citations

Abstract

This is the first report of the Southwest oncology group phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma (NHL). Fifty-two patients in first or second relapse with diffuse large B-cell or mantle cell lymphoma were enrolled. Patients were treated with bevacizumab at 10 mg/kg every 2 weeks. Therapy was well tolerated with no unexpected toxicities observed. Six-month progression-free survival (PFS) was 16% with a response rate of 2% and median duration of response or stable disease of 5.2 months (range 3.5-72.7). Vascular endothelial growth factor A (VEGF) and VEGF receptor expression was observed in 70% and 65% of specimens, respectively. In an exploratory subgroup analysis, baseline urine VEGF and plasma vascular cell adhesion molecule-1 (VCAM) levels correlated with survival. Prolonged PFS in several patients as well as biomarker studies suggest the VEGF pathway plays an important role in aggressive NHL. Clinical trials combining active chemotherapy regimens with VEGF targeted agents are currently in progress.

Original language	English (US)
Pages (from-to)	728-735
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	50
Issue number	5
DOIs	https://doi.org/10.1080/10428190902856808
State	Published - 2009

Keywords

Bevacizumab
Clinical trial
Non-Hodgkin lymphoma
VEGF

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428190902856808

Cite this

@article{906225e873324f829a01bfc3a514e651,

title = "A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108",

abstract = "This is the first report of the Southwest oncology group phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma (NHL). Fifty-two patients in first or second relapse with diffuse large B-cell or mantle cell lymphoma were enrolled. Patients were treated with bevacizumab at 10 mg/kg every 2 weeks. Therapy was well tolerated with no unexpected toxicities observed. Six-month progression-free survival (PFS) was 16% with a response rate of 2% and median duration of response or stable disease of 5.2 months (range 3.5-72.7). Vascular endothelial growth factor A (VEGF) and VEGF receptor expression was observed in 70% and 65% of specimens, respectively. In an exploratory subgroup analysis, baseline urine VEGF and plasma vascular cell adhesion molecule-1 (VCAM) levels correlated with survival. Prolonged PFS in several patients as well as biomarker studies suggest the VEGF pathway plays an important role in aggressive NHL. Clinical trials combining active chemotherapy regimens with VEGF targeted agents are currently in progress.",

keywords = "Bevacizumab, Clinical trial, Non-Hodgkin lymphoma, VEGF",

author = "Stopeck, {Alison T.} and Unger, {Joseph M.} and Rimsza, {Lisa M.} and Bellamy, {William T.} and Maria Iannone and Daniel Persky and Michael Leblanc and Richard Fisher and Thomas Miller",

note = "Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA32102, CA38926, CA13612, CA37981, CA11083, CA35431, CA35261, CA58861, CA67663, CA64282, CA45560, CA12644, CA67575, CA35176, CA45807, CA20319, CA35119, CA35192, CA46441, CA35090, CA22433 and in part by the Translational Research Grant from The Leukemia and Lymphoma Society.",

year = "2009",

doi = "10.1080/10428190902856808",

language = "English (US)",

volume = "50",

pages = "728--735",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma

T2 - Southwest oncology group study S0108

AU - Stopeck, Alison T.

AU - Unger, Joseph M.

AU - Rimsza, Lisa M.

AU - Bellamy, William T.

AU - Iannone, Maria

AU - Persky, Daniel

AU - Leblanc, Michael

AU - Fisher, Richard

AU - Miller, Thomas

N1 - Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA32102, CA38926, CA13612, CA37981, CA11083, CA35431, CA35261, CA58861, CA67663, CA64282, CA45560, CA12644, CA67575, CA35176, CA45807, CA20319, CA35119, CA35192, CA46441, CA35090, CA22433 and in part by the Translational Research Grant from The Leukemia and Lymphoma Society.

PY - 2009

Y1 - 2009

N2 - This is the first report of the Southwest oncology group phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma (NHL). Fifty-two patients in first or second relapse with diffuse large B-cell or mantle cell lymphoma were enrolled. Patients were treated with bevacizumab at 10 mg/kg every 2 weeks. Therapy was well tolerated with no unexpected toxicities observed. Six-month progression-free survival (PFS) was 16% with a response rate of 2% and median duration of response or stable disease of 5.2 months (range 3.5-72.7). Vascular endothelial growth factor A (VEGF) and VEGF receptor expression was observed in 70% and 65% of specimens, respectively. In an exploratory subgroup analysis, baseline urine VEGF and plasma vascular cell adhesion molecule-1 (VCAM) levels correlated with survival. Prolonged PFS in several patients as well as biomarker studies suggest the VEGF pathway plays an important role in aggressive NHL. Clinical trials combining active chemotherapy regimens with VEGF targeted agents are currently in progress.

AB - This is the first report of the Southwest oncology group phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma (NHL). Fifty-two patients in first or second relapse with diffuse large B-cell or mantle cell lymphoma were enrolled. Patients were treated with bevacizumab at 10 mg/kg every 2 weeks. Therapy was well tolerated with no unexpected toxicities observed. Six-month progression-free survival (PFS) was 16% with a response rate of 2% and median duration of response or stable disease of 5.2 months (range 3.5-72.7). Vascular endothelial growth factor A (VEGF) and VEGF receptor expression was observed in 70% and 65% of specimens, respectively. In an exploratory subgroup analysis, baseline urine VEGF and plasma vascular cell adhesion molecule-1 (VCAM) levels correlated with survival. Prolonged PFS in several patients as well as biomarker studies suggest the VEGF pathway plays an important role in aggressive NHL. Clinical trials combining active chemotherapy regimens with VEGF targeted agents are currently in progress.

KW - Bevacizumab

KW - Clinical trial

KW - Non-Hodgkin lymphoma

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=67650866822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650866822&partnerID=8YFLogxK

U2 - 10.1080/10428190902856808

DO - 10.1080/10428190902856808

M3 - Article

C2 - 19373598

AN - SCOPUS:67650866822

SN - 1042-8194

VL - 50

SP - 728

EP - 735

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5

ER -

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this